Citadel Advisors
MRNA icon

Citadel Advisors’s Moderna MRNA Stock Holding History

Citadel Advisors’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$24.9M Sell
489,770
-89,360
-15% -$4.17M ﹤0.01% 2063
2025
Q4 		$17.1M Sell
579,130
-1,408,601
-71% -$38.3M ﹤0.01% 2548
2025
Q3 		$51.3M Buy
1,987,731
+153,023
+8% +$4.27M 0.01% 1354
2025
Q2 		$50.6M Buy
1,834,708
+74,423
+4% +$1.96M 0.01% 1237
2025
Q1 		$49.9M Buy
1,760,285
+988,393
+128% +$35.1M 0.01% 1146
2024
Q4 		$32.1M Buy
771,892
+519,516
+206% +$24.8M 0.01% 1682
2024
Q3 		$16.9M Sell
252,376
-208,080
-45% -$19.1M ﹤0.01% 2238
2024
Q2 		$54.7M Buy
460,456
+188,119
+69% +$23.8M 0.01% 1082
2024
Q1 		$29M Sell
272,337
-268,679
-50% -$27.1M 0.01% 1696
2023
Q4 		$53.8M Buy
541,016
+35,601
+7% +$2.99M 0.01% 1123
2023
Q3 		$52.2M Buy
505,415
+406,060
+409% +$45.3M 0.01% 1041
2023
Q2 		$12.1M Sell
99,355
-123,630
-55% -$16.5M ﹤0.01% 2431
2023
Q1 		$34.2M Buy
222,985
+122,347
+122% +$20.2M 0.01% 1418
2022
Q4 		$18.1M Buy
100,638
+17,061
+20% +$2.79M ﹤0.01% 2074
2022
Q3 		$9.88M Sell
83,577
-7,382
-8% -$1.12M ﹤0.01% 2787
2022
Q2 		$13M Buy
90,959
+70,149
+337% +$10M ﹤0.01% 2348
2022
Q1 		$3.58M Sell
20,810
-498,642
-96% -$83.9M ﹤0.01% 4827
2021
Q4 		$132M Buy
519,452
+243,006
+88% +$71.1M 0.03% 520
2021
Q3 		$106M Sell
276,446
-438,233
-61% -$162M 0.02% 624
2021
Q2 		$168M Sell
714,679
-517,219
-42% -$92.4M 0.04% 403
2021
Q1 		$161M Buy
1,231,898
+146,980
+14% +$21.3M 0.04% 374
2020
Q4 		$113M Buy
1,084,918
+1,068,494
+6,506% +$108M 0.03% 477
2020
Q3 		$1.16M Sell
16,424
-40,077
-71% -$2.79M ﹤0.01% 5759
2020
Q2 		$3.63M Buy
56,501
+46,262
+452% +$2.53M ﹤0.01% 3543
2020
Q1 		$307K Sell
10,239
-85,786
-89% -$1.97M ﹤0.01% 7303
2019
Q4 		$1.88M Buy
96,025
+24,310
+34% +$431K ﹤0.01% 4513
2019
Q3 		$1.14M Sell
71,715
-630,763
-90% -$9.32M ﹤0.01% 5367
2019
Q2 		$10.3M Buy
702,478
+543,370
+342% +$11.7M ﹤0.01% 2143
2019
Q1 		$3.24M Buy
+159,108
New +$2.95M ﹤0.01% 3632

Other funds holding MRNA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Citadel Advisors's MRNA Position: Q1 2026 in Review

Citadel Advisors reduced its Moderna (MRNA) stake by 15% in Q1 2026, selling an estimated $4.17M and leaving 489,770 shares worth $24.9M. The position accounts for ﹤0.01% of the portfolio, ranked #2063.

Citadel Advisors first reported a position in MRNA in Q1 2019 and has held it in 29 quarters since. The position peaked at $168M in Q2 2021. 722 funds tracked by Wall St. Rank hold MRNA as of Q1 2026.

  • Citadel Advisors held 489,770 shares of Moderna worth $24.9M as of Q1 2026.
  • Citadel Advisors sold 89,360 Moderna shares in Q1 2026, an estimated $4.17M.
  • Moderna made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #2063 holding.
  • Citadel Advisors first reported a position in Moderna in Q1 2019 and has held it in 29 quarters since.
  • Citadel Advisors's Moderna position peaked at $168M in Q2 2021.
  • 722 funds tracked by Wall St. Rank held Moderna as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.